AvKARE Recalls Losartan Potassium Tablets Due to Impurity
AvKARE Inc. is recalling Losartan Potassium Tablets 50 mg because FDA testing found an impurity above acceptable levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the presence of a nitrosamine impurity (NMBA) above acceptable levels constitutes a significant health risk, aligning with the 'Severe' criteria for significant injury/health risk reports.
Plain-English summary
AvKARE Inc. is recalling Losartan Potassium Tablets USP 50 mg, 50 tablets (5x10) Unit Dose, NDC 50268-517-15. The recall involves 1,438 cartons containing 71,900 tablets. The affected lot number is 20121 with an expiration date of 6/30/2019. The product was distributed nationwide.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. FDA laboratory testing confirmed the presence of the impurity N-Methylnitrosobutyric acid (NMBA) in the finished product at levels exceeding the interim acceptable daily intake limit of 0.96 parts per million.
Consumers and healthcare providers should stop using the affected tablets and contact their pharmacist or healthcare provider for guidance on alternative treatment options.
The recalled product
- Product
- Losartan Potassium Tablets USP 50 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-517-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478
- Manufacturer
- AVKARE Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 20121 Exp. 6/30/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by AVKARE Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · AVKARE Inc.
See all →- ModerateLamotrigine Tablets Recalled for Label Strength Error
FDA (Drugs) · 2022-08-17
- ModeratePhytonadione Tablets 5 mg Recalled Due to Failed Impurities Specification
FDA (Drugs) · 2021-06-23
- CriticalAvKare Recalls Trazodone Hydrochloride Tablets Due to Sildenafil Packaging Mix-Up
FDA (Drugs) · 2020-12-23
- ModerateAvKARE Recalls Sildenafil Tablets Due to Packaging Mix-Up with Trazodone
FDA (Drugs) · 2020-12-23
- ModerateAvKARE Recalls Mesalamine Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-11-18
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17